Abstract: A solid pharmaceutical dosage form that is safeguarded against abuse containing at least one active substance that could be subject to abuse and at least one antagonist for the active substance, which antagonist is spatially separate from the active substance. The active substance or substances is/are present in at least one subunit (a), and the at least one antagonist is present in at least one subunit (b), and the at least one antagonist in subunit (b) is to all intents and purposes not released in the body if the dosage form is correctly administered as prescribed.

Abstract: A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed.

Abstract: A pharmaceutical dosage form that is safeguarded against abuse containing at least one active substance that is susceptible to abuse and at least two of the following constituents (a) through (d): (a) at least one substance that irritates the nasal and/or pharyngeal region; (b) at least one viscosity increasing agent that together with a required minimum quantity of an aqueous liquid forms a gel in an extract obtained from the dosage form, which gel can still be discerned after being introduced into an additional quantity of aqueous liquid; (c) at least one antagonist for the at least one active substance that is susceptible to abuse; and (d) at least one emetic.

Abstract: A solid pharmaceutical dosage form that is safeguarded against abuse containing at least one active substance that could be subject to abuse and at least one antagonist for the active substance, which antagonist is spatially separate from the active substance. The active substance or substances is/are present in at least one subunit (a), and the at least one antagonist is present in at least one subunit (b), and the at least one antagonist in subunit (b) is to all intents and purposes not released in the body if the dosage form is correctly administered as prescribed.

Abstract: A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed.

Abstract: The invention relates to a method for detecting and determining mediators and/or their derivatives in fluids, the mediator being detected directly or indirectly with the aid of a recombinant, soluble receptor for the mediator to be detected.

Abstract: The invention relates to a process for the decontamination of cell cultures containing mycoplasmas. In this process the cell cultures infected by mycoplasmas undergo an antibiotic treatment in a first step, and cells still infected are then eliminated by 6-methylpurine deoxyriboside solution in a second step.

Abstract: The present invention relates to a composition containing the p40 subunit of interleukin-12, hereinafter referred to as p40/IL-12 and to methods of diagnosis and treatment of disorders associated with disregulation of the immune system.